Streptokinase is highly purified Streptokinase obtained from the culture filtrate of beta-haemolytic Streptococci of group C. Streptokinase acts with plasminogen to produce an ‘activator complex’ that converts plasminogen to the proteolytic enzyme, plasmin. The more plasminogen bound within this complex, the less plasminogen is left to be converted into its enzymatically active form. Therefore, high doses of Streptokinase are associated with a lower bleeding risk and low doses of Streptokinase are associated with a higher bleeding risk.
S-Kinase Powder for Injection
Acute myocardial infarction:
Adult: 1.5 million units as a single dose infused over 1 hr immediately after onset of symptoms.
Pulmonary thromboembolism, Arteriovenous occlusions:
Adult: Loading dose: 250,000 units infused over 30 min. Maintenance: 100,000 units/hr for 24-72 hr depending on the condition to be treated. For cerebral retinal thrombosis, 12 hr may be sufficient. Monitor treatment by maintaining thrombin clotting time at 2-4 times normal values.
Child: Loading dose: 2500-4000 units/kg over 30 min, followed by infusion of 500-1000 units/kg/hr, continued until reperfusion occurs, up to 3 days. Initial dose may be estimated by streptokinase resistance test. Monitor treatment by maintaining thrombin clotting time at 2-4 times normal values.